A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Clinical trial NCT01715818 · COMPLETED
Trial details
- NCT number
- NCT01715818
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-12-01
- Primary completion
- 2013-11-01
- Enrollment
- 1999
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.